Clinical-stage biotechnology company Latigo Biotherapeutics Inc. (Latigo) announced on Monday that it has named Tim Lugo as its new chief financial officer (CFO).
Lugo has two decades of experience as a financial analyst covering the biotechnology and pharmaceutical sectors. He has served as a partner and group head of biotechnology equity research at William Blair. He has also worked at Pacific Growth Equities as a junior analyst. He serves on the board of trustees at Children's Day School in San Francisco.
Lugo has a BA in molecular and cellular biology and a BA in economics, both from the University of California, Berkeley.
Sareum Holdings secures patent allowance for SDC-1801 in China
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval